Analysis of Winning Advertisements
Agenda
• Recap Past Studies• Review Objectives• Review Criteria• Evaluate New Rx Performance for Winners• Next Steps
Perspective
• Does Journal Advertising Work?• Does Advertising Have an Impact on Rxs?• How Much Advertising is Necessary?
Chronology and review of significant research
ROI Analysis of Pharmaceutical PromotionLandmark study historical data for 1995-99391 drugs, 16,696 monthly observationsDetermined marginal ROI
JAD, $5.00 +/- $0.88PME, $3.56 +/- $1.92DET, $1.72 +/- $0.19DTC, $0.19 +/- $0.52
Dartmouth Marginal ROI Study, 2001RAPP
• Analysis of ROI for Pharmaceutical Promotion– Extended data 1995-2000; 21,436 monthly observations– Examples of findings:
• $500M+/1998-2000: All tactics generate positive returns for average brand, but under spending on JAD and PME
– Additional spend on journals could have very positive returns for both small brands and large brands
Yale Marginal ROI Study, 2002ARPP
•Select targeted physician specialties•Oncology•Pulmonary Disease•Psychiatry•Neurology
• Analyze Top 10 Products for Each Specialty• Spend levels• Reach & Frequency Levels
Baseline Study10 month advertising campaign
Follow-up StudyEvaluate Results
Total of 203 insertions$1,083,466 in advertising space
•Oncology - $73,280•Pulmonary Disease - $91,925•Neurology - $99,639•Psych - $105,398•Primary Care - $432,577
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
Baseline Post-Campaign
Yes 24% 45%
No 74% 54%
Not Sure 2% 1%
The Awareness increased by 89%!
Are you aware of the availability of the Directory of Prescription Drug Patient Assistance Programs, from (PhRMA)?
• Neurologists were exposed least (43%/mo)– Awareness increased 69%
• Pulmonary Disease were exposed most (75%/mo)– Awareness increased by 117%
Two Product-Specific StudiesDesigned to measure the relationship of detailing and print advertising
• Select two products in major therapeutic areas– No previous PCP promotion– Patent-protected– One year test period
• Four Cells of 16,000 PCP’s– Control Group– Low level of promotion– Average level of promotion– High level of promotion
• Pretest each advertisement• Launch Campaigns• Six Month PosTest
– Ad Recognition– Product Recall– Correct Message Association– New Rx’s
• New Rx Analysis• Twelve Month Results
• “B” PreTest– 57% physicians unsure/negative
• too busy, too crowded, too much information– Recommended to change ad size from 2 pages to 4 pages– Not Done
• Subsequent change of detail message
Metrics did not change: PCP NRx
Mar-Aug ‘03 Mar-Aug ‘04 % Change
Control 5,707 8,287 45.2%
Cell I 5,438 7,845 44.3%
Cell II 5.946 8,718 46.5%
Cell III 6,713 9,650 43.8%
• “A” PreTest– Good pretest acceptance– Accepted visual elements– Accepted headline
• Recommended message simplification– adjusted
1116
23
44
05
1015202530354045
Control Low Cell Average Cell High Cell
Product Recall – six months
21
44 45
58
0
10
20
30
40
50
60
Control Low Cell Average Cell High Cell
Ad Recognition – six months
05
1015202530354045
Control Low Cell Average Cell High Cell
3229 26
44
Correct Message Association – six months
0
20
40
60
Control Low Cell Average Cell High Cell
..
40% 40% 41% 42%
43% 38%46% 52%
Company Records
Physicians’ Perception
Perception of Detailing – six months
First Choice Therapy
31 3032
38
0
5
10
15
20
25
30
35
40
Percent
Control Cell 1 Cell 2 Cell 3
Product “A” Six Month PosTest
0.1
9.79
0.1
11.07
02468
1012
% change
1st 6 Months 2nd 6 Months
ControlHigh cell
Change in NRx
9.79
11.07 11.16
9
9.5
10
10.5
11
11.5
% change
1st 6Months
2nd 6Months
Post TestPeriod
High cell
(8 months)
Change in NRx
Doctor’s Choice Awards
Journal Advertisement Attributes – Doctors’ Choice Questionnaire
• Prompts seeking more information or re-examination of treatment• Helps with clinical decisions• Adds to information provided by company representative
• Has immediate appeal to gain interestHas immediate appeal to gain interest• Communicates clearly and quickly
• Reminds about value of product prescribed
Doctor's Choice Awards 2006
• Majority of winning advertisement achieved increased New Rx's
Doctor's Choice Awards 2007
• Newest findings
Once again, the overwhelming majority of winners gained New Rx marketshare
New Rx's data contributed by VerispanReach & Frequency data contributed by MARS Medical
Lipitor
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
CardiovascularsCardiovasculars
Lipitor
73
84
80
76
66687072747678808284
GP FP IM CA
*This is read as 76% of the Card universe was exposed *This is read as 76% of the Card universe was exposed to the Lipitor ad each month of the campaignto the Lipitor ad each month of the campaign
Zovirax
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Generic environmentGeneric environment
DermatologicalsDermatologicals
Zovirax
54
0
10
20
30
40
50
60
Derm
Novolog FlexPen
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
DiabetesDiabetes
Novolog FlexPen
49
05101520253035404550
Diabetes/Endo
Zyvox
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Amoxicillin in group
Anti-InfectivesAnti-Infectives
Zyvox
82
0102030405060708090
ID
Halflytely
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
GastroenterologicalsGastroenterologicals
Halflytely
62
0
10
20
30
40
50
60
70
Gastro
Keppra
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
NeurologicalsNeurologicals
Keppra
62
0
10
20
30
40
50
60
70
Neuro
NuvaRing
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
Obstetricals/GynecologicalsObstetricals/Gynecologicals
NuvaRing
73
0
10
20
30
40
50
60
70
80
OB/GYN
Tarceva
0.00%
0.20%
0.40%
0.60%
0.80%
1.00%
1.20%
OncologicalsOncologicals
Tarceva
83
0102030405060708090
Oncologists
Gardasil
0
0.05
0.1
0.15
0.2
0.25
PediatricsPediatrics
Gardasil
5760
36
54
0
10
20
30
40
50
60
GP FP IM Ped
Lunesta
12.00%
12.50%
13.00%
13.50%
14.00%
14.50%
15.00%
PsychiatricsPsychiatrics
Lunesta
73
85
7468
47
0102030405060708090
GP FP IM PSY OB
Flomax
36.00%36.50%37.00%37.50%38.00%38.50%39.00%39.50%40.00%40.50%41.00%
UrologicalUrological
Flomax
88
0102030405060708090
Uro
Conclusions
• Identify effective messages/creative • Measure New Rx’s Over Time• Successful messages are effective with ample execution
The winning products continue to demonstrate success in recognition and performance